Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05980546 · ClinicalTrials.gov registry record · Phase 4
Genicular and Anterior Femoral Cutaneous Nerve Blocks for Total Knee Arthroplasty
A Phase 4 study, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- Phase 4
- Development phase
- 244
- Enrollment target
NCT05980546 is a Phase 4 study that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 244 participants.
The verdict
NCT05980546, a Phase 4 study, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 244 participants
- Enrollment target
Study Summary
The goal of this randomized controlled trial is to examine if there is a relationship between the addition of the genicular nerve block and anterior femoral cutaneous nerve block in providing analgesia and the use of oral and intravenous medication in patients undergoing a total knee arthroplasty. The main questions it aims to answer are: 1. Does incorporating genicular nerve block and anterior femoral cutaneous nerve block to our current standard of care reduce patients' total opioid consumption in the first 24 hours after total knee arthroplasty (TKA) surgery? 2. Does incorporating genicular nerve block and anterior femoral cutaneous nerve block to our current standard of care reduce patients' worst numeric rating scale (NRS) pain score in the post-anesthesia care unit (PACU)? 3. Does incorporating genicular nerve block and anterior femoral cutaneous nerve block to our current standard of care result in earlier discharge from the post-anesthesia care unit (PACU)? 4. Does incorporating genicular nerve block and anterior femoral cutaneous nerve block to our current standard of care reduce patients' total opioid consumption in the first 7 days after total knee arthroplasty (TKA) surgery? 5. Does incorporating genicular nerve block and anterior femoral cutaneous nerve block to our current standard of care reduce patients' numerical rating scale (NRS) pain (both at rest and during movement) in the first 24 and 48 hours after surgery? Participants will be randomly assigned to receive the genicular nerve block and anterior femoral cutaneous nerve block in addition to standard of care (intervention group), or not receive the nerve blocks (control group). Comparing the intervention group to the control group, the researcher's primary outcomes are numerical pain in the post-anesthesia care unit and cumulative opioid consumption during the first 24 hours.
Interventions
- DRUG Mepivacaine
- DRUG Bupivacaine Injection
- DRUG Fentanyl
- DRUG Dexamethasone injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2023-06-07 |
| Est. Completion | 2025-09-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05980546
The ClinicalTrials.gov registry entry for NCT05980546 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Mepivacaine is the first listed.
NCT05980546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05980546 about?
NCT05980546 is a clinical study titled "Genicular and Anterior Femoral Cutaneous Nerve Blocks for Total Knee Arthroplasty". The goal of this randomized controlled trial is to examine if there is a relationship between the addition of the genicular nerve block and anterior femoral cutaneous nerve block in providing analgesia and the use of oral and intravenous medication in patients undergoing a total knee arthroplasty. T...
What is the current status of trial NCT05980546?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 244 participants. The study started on 2023-06-07. Estimated completion is 2025-09-11.
What interventions are being tested in trial NCT05980546?
The interventions under investigation include: Mepivacaine (DRUG), Bupivacaine Injection (DRUG), Fentanyl (DRUG), Dexamethasone injection (DRUG).
Who is sponsoring clinical trial NCT05980546?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.